Physician profile
Sarah Moore
NPI 1265994891
$4,961.29
in general payments reported to CMS, 2019-2025
24 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $429 · 2024: $2,561 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,780 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.13 |
| Education | $181.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $661.06 | 2024 | Vtama |
| Ucb, INC. | $514.80 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $476.89 | 2023-2025 | Sotyktu |
| Amgen INC. | $474.62 | 2023-2025 | Otezla, Otezla |
| Abbvie INC. | $471.94 | 2024-2025 | |
| Janssen Biotech, INC. | $421.20 | 2024-2025 | Tremfya |
| Pfizer INC. | $410.30 | 2023-2025 | |
| Lilly USA, LLC | $357.91 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $223.95 | 2024-2025 | Aklief, Nemluvio |
| Incyte Corporation | $182.93 | 2024-2025 | Opzelura |
| Organon LLC | $180.73 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $153.10 | 2023-2025 | Zoryve |
| Genzyme Corporation | $94.36 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $92.88 | 2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $60.65 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Almirall LLC | $29.01 | 2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $22.98 | 2024 | Ycanth |
| Genentech USA, INC. | $18.84 | 2024 | Erivedge |
| Botanix Sb INC | $15.97 | 2025 | Sofdra |
| Bayer Healthcare Pharmaceuticals INC. | $15.91 | 2024 | |
| Revance Therapeutics, INC. | $14.81 | 2025 | Daxxify |
| Tempus Ai, INC | $14.41 | 2024 | Merlin Test |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.